Compare Alcon AG (ALC) vs ON Holding AG (ONON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs ON Holding AG — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while ON Holding AG trades at $35.86 (market cap $12.21B). The key difference: Alcon AG is far larger — about 2.7× ON Holding AG's market cap, and Alcon AG pays a 0.54% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| ALC | ONON | |
|---|---|---|
Market Cap | $32.69B | $12.21B |
Sector | Health | Technology |
52-Week High | $92.22 | $54.24 |
52-Week Low | $62.02 | $31.88 |
Enterprise Value | $36.28B | $11.53B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ONON trades at $36.87, up 0.11% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 63.88% gross margin and 15.5% ROE, supported by revenue growth to $3.01B in 2025. Analyst consensus is bullish with a $47.33 price target, though technical indicators suggest near-term resistance.
The outlook remains positive given consistent earnings outperformance and raised profit guidance, but risks include tariff concerns and competitive pressures. Upside potential exists if the company maintains its innovation-led growth, particularly in Asia-Pacific markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
